SUBSCRIBE
SUBSCRIBE
News   Drug Development

Idera Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications

January 28, 2010 | 
1 min read

Bookmark and Share

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

Clinical research Phase I
MORE ON THIS TOPIC
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
December 12, 2024
 · 
3 min read
 · 
Tristan Manalac
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Immunology and inflammation
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology
Partnered
Ending the Diagnostic Odyssey for Patients
December 11, 2024
 · 
4 min read
 · 
BioSpace Insights
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac